Stelfonta

RSS

tigilanol tiglate

Authorised
This medicine is authorised for use in the European Union.

Overview

Stelfonta is a cancer veterinary medicine used in dogs to treat mast cell tumours that are not suitable for surgery and that have not spread to other parts of the body. These tumours are a type of cancer involving mast cells. These are immune system cells, found in many tissues, that release substances such as histamine. Stelfonta is used for mast cell tumours in the skin, or in mast cell tumours in the tissues just under the skin at or below the elbow or hock. Stelfonta contains the active substance tigilanol tiglate. How is Stelfonta used?

This EPAR was last updated on 13/05/2020

Authorisation details

Product details
Name
Stelfonta
Agency product number
EMEA/V/C/005018
Active substance
tigilanol tiglate
International non-proprietary name (INN) or common name
tigilanol tiglate
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QL01XX
Publication details
Marketing-authorisation holder
QBiotics Netherlands B.V.
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
15/01/2020
Contact address

Prinses Margrietplantsoen 33
2595 AM
The Hague
Netherlands

Product information

30/04/2020 Stelfonta - EMEA/V/C/005018 - IB/0002

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

tigilanol tiglate

Therapeutic indication

For the treatment of non-resectable, non-metastatic (WHO staging) subcutaneous mast cell tumours located at or distal to the elbow or the hock, and non-resectable, non metastatic cutaneous mast cell tumours in dogs.

Assessment history

How useful was this page?

Add your rating
Average
1 rating